PhaseBio Pharmaceuticals, Inc. (PHAS) Stock: Is This Biotechnology Stock Worth Your Consideration?


PhaseBio Pharmaceuticals, Inc. (PHAS) is trending down in the market today. The company, one that is focused in the biotech industry, is presently trading at $10.83 after a move down of -7.20% so far today. As it relates to biotechnology companies, there are a number of aspects that have the potential to cause declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines relating to PHAS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-09-19 04:01PM PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress
May-02-19 08:00AM PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019
Apr-25-19 09:23AM 2 Ultra-High Growth Stocks to Buy Now
Apr-17-19 04:00AM PhaseBio completes $49.5M stock sale
Apr-16-19 04:01PM PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares

However, when making an investing decision, investors should look into much more than news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening in regard to PhaseBio Pharmaceuticals, Inc..

Recent Movement From PHAS

Although a move toward the top in a single session, like what we’re seeing from PhaseBio Pharmaceuticals, Inc. might cause fear in some investors, a single session move by itself should not be the reason for a decision to, or not to, buy a company’s stock. It’s generally important to dig into trends further out than a single session. As it relates to PHAS, here are the returns that investors have seen:

  • Past 7 Days – Over the last 7 days, PHAS has produced a change in price that amounts to -12.19%.
  • Past Month – The monthly ROI from PhaseBio Pharmaceuticals, Inc. works out to -11.99%.
  • Quarterly – Throughout the past 3 months, the stock has produced a return on investment of 290.30%
  • Past Six Months – Throughout the past 6 months, we’ve seen a change of 132.93% from the stock.
  • YTD – Since the the first trading session of this year PHAS has generated a return of 277.67%.
  • Annually – Lastly, in the past year, investors have seen movement amounting to 0 out of PHAS. Over this period of time, the stock has sold at a high of -34.95% and a low price of 324.71%.

Ratios To Pay Attention To

Looking at various key ratios associated with a stock can provide investors an understanding of how risky and/or rewarding a stock pick may be. Below are some of the important ratios to think about when looking at PHAS.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it means that more investors are expecting that the price of the stock is headed for declines. In general, biotechnology stocks can have a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the sector. Nonetheless, as it relates to PhaseBio Pharmaceuticals, Inc., the stock’s short ratio amounts to 2.15.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure If a company is able to pay for its debts when they mature with only quick assets or current assets. In the biotechnology industry, many companies rely on continued investor support, the quick and current ratios can look upsetting. However, some good picks in the biotechnology space come with good quick and current ratios. In terms of PHAS, the quick and current ratios come to 13.70 and 13.70 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets owned by the company. In this case, that ratio is 2.08.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a biotech stock, this is an important ratio to look into. When it comes to PHAS, the cash to share value ratio comes to 2.20.

What Analysts Say About PhaseBio Pharmaceuticals, Inc.

Although it’s not a smart idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to consider their analysis in order to validate your own thoughts before making investment decisions in the biotech sector. Below you’ll find the most recent moves that we have seen from analysts with regard to PHAS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-13-18 Initiated Needham Buy $18
Nov-12-18 Initiated Stifel Buy $14
Nov-12-18 Initiated Citigroup Buy $18

Is Big Money Interested in PhaseBio Pharmaceuticals, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PHAS, here’s what we’re seeing:

  • Institutions – At the moment, institutional investors hold 56.90% of the company. However, it is worth noting that institutional ownership has seen a move of 0.16% in the last 3 months.
  • Insider Holdings – as it relates to insiders, those close to the situation currently own 0.10% of the company. Their ownership of the company has changed in the amount of 0 over the past 3 months.

What’s The Float Looking Like?

Investors and traders seem to have an interest in the counts of shares both outstanding and available. As it relates to PhaseBio Pharmaceuticals, Inc., there are currently 27.77M and there is a float of 22.42M. These data mean that of the total of 27.77M shares of PHAS in existence today, 22.42M are available to be traded in the public space.

I also like to take a look at the short percentage of the float. Think about it, when a large portion of the float available for trading is sold short, the overall opinion among traders is that the stock is going to take a dive. As far as PHAS, the percentage of the float that is sold short comes to a total of 4.96%. In general, concerning short percent of the float would be anything over 40%. Through my work, I’ve seen that a short ratio over 26% is usually a a play that could prove to be very risky.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.65. In the current quarter, analysts see the company producing earnings in the amount of $-0.34. Over the last 5 years, PHAS has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -52.00% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was created by a human and human beings actually play a crucial role in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I am able to learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here